EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging

Ping Bai, Ashley Gomm, Chi-Hyeon Yoo, Prasenjit Mondal, Fleur Marie Lobo, Hui Meng, Yanting Zhou, Weiyao Xie, Hsiao-Ying Wey, Rudolph E Tanzi, Can Zhang, Changning Wang iD und 1 weitere

Advanced Science · 2025

DOI: 10.1002/advs.202414827 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Ping Bai und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, C…. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Receptors, sigma, Brain, Carbon Radioisotopes. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, Central Guidance for Local Science and Technology Development Projects, Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The sigma‐1 receptor (σ1R) is a stress‐activated chaperone protein that has emerged as a significant therapeutic target for neurodegenerative disorders. Developing effective positron emission tomography (PET) imaging probes targeting σ1R is crucial for visualizing its distribution and function in the brain, as well as facilitating related drug development. In this study, two novel 11 C‐labeled PET probes based on the structure of a potent σ1R ligand Lan‐0101 are designed and synthesized. PET imaging studies in mice reveal that [ 11 C]CNY‐01 exhibits good brain uptake and binding specificity. Subsequent evaluation in non‐human primates further demonstrates that [ 11 C]CNY‐01 displays favorable brain penetration, slow clearance kinetics, and characteristics of irreversible binding to its target in blockage experiments. To assess the clinical potential of the probe, both in vitro experiments and in vivo PET imaging using [ 11 C]CNY‐01 are conducted in Alzheimer's disease (AD) transgenic mouse models. These studies reveal a significant decrease in σ1R expression in the brain under conditions of AD amyloid pathology and microglial activation, highlighting the probe's sensitivity to disease‐related receptor changes. This work establishes [ 11 C]CNY‐01 as a promising tool for investigating the relationship between σ1R and neurological disorders, potentially advancing the understanding of σ1R's role in disease pathophysiology and therapeutic interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyReceptors, sigmaBrainCarbon RadioisotopesPyrimidinesAlzheimer DiseaseAnimalsSigma-1 ReceptorMiceMice, TransgenicRadiopharmaceuticalsDisease Models, AnimalHumans

Stichwörter der Autor:innen

11C‐labeled radioligandbrain PET imagingpyrimidine derivativessigma‐1 receptor (σ1R)

Substanzen

Sigma-1 ReceptorReceptors, sigmaCarbon RadioisotopesCarbon-11PyrimidinesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Respiratory and Critical Care Medicine, Targeted Tracer Research and Development Laboratory, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • Institute of Respiratory Health, Targeted Tracer Research and Development Laboratory, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, Ch…
  • Precision Medicine Center, Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, China.
  • The Research Units of West China, Chinese Academy of Medical Sciences, West China Hospital, Chengdu, Sichuan, 610041, China.
  • State Key Laboratory of Respiratory Health and Multimorbidity, West China Hospital, Chengdu, Sichuan, 610041, China.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, Mass General Institute for Neurodegenerative Disease, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, 114 16th Street,…

ORCID-Profile: Changning Wang

Förderung

  • NIH HHS
  • Central Guidance for Local Science and Technology Development Projects
  • Athinoula A. Martinos Center for Biomedical Imaging at the Massachusetts General Hospital
  • National Institutes of Health

Zitieren

APA

Bai, P., Gomm, A., Yoo, C. H., Mondal, P., Lobo, F. M., Meng, H., Zhou, Y., Xie, W., Wey, H. Y., Tanzi, R. E., Zhang, C., Wang, C., & Lan, Y. (2025). Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging. Advanced Science. https://doi.org/10.1002/advs.202414827

Vancouver

Bai P, Gomm A, Yoo CH, Mondal P, Lobo FM, Meng H, et al. Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging. Advanced Science. 2025. doi:10.1002/advs.202414827

BibTeX
@article{Bai2025,
  author = {Bai, Ping and Gomm, Ashley and Yoo, Chi-Hyeon and Mondal, Prasenjit and Lobo, Fleur Marie and Meng, Hui and Zhou, Yanting and Xie, Weiyao and Wey, Hsiao-Ying and Tanzi, Rudolph E and Zhang, Can and Wang, Changning and Lan, Yu},
  title = {Development of Carbon‐11 Labeled Pyrimidine Derivatives as Novel Positron Emission Tomography (PET) Agents Enabling Brain Sigma‐1 Receptor Imaging},
  journal = {Advanced Science},
  year = {2025},
  doi = {10.1002/advs.202414827}
}
Kostenlos starten →